Three-quarters of patients diagnosed with cancer report decreased physical activity.
In contrast with current guidelines, non-conventional physical activity patterns reduce all-cause, cardiovascular disease (CVD), and cancer mortality.
Model predicts that women at the highest risk of breast cancer are no more at risk than the general population if they do not smoke, drink alcohol, use menopausal hormone therapy, and have a low BMI.
Adolescent exercise was found to be associated with a decreased risk of death caused by cancer, cardiovascular disease (CVD).
For breast and colorectal cancer survivors, level of exercise participation significantly increased with oncologist recommendations.
For breast cancer survivors, slowly progressive weight lifting can reduce the incidence of physical function deterioration.
Cycling may have no effect on PSA levels in men with prostate cancer as previously thought.
For women undergoing adjuvant chemotherapy for breast cancer, a high-intensity physical activity program is most effective.
Findings in a quasi-experimental study of Taiwanese women with early-stage breast cancer.
Researchers identify a relationship between exercise activity and television habits in relation to mortality in survivors of colorectal cancer.
Alternative therapies may be safely combined with traditional cancer treatments.
For breast cancer survivors, post-diagnosis running is associated with reduced mortality versus walking.
Researchers found a lower risk of all-cause mortality and mortality from cancer and cardiovascular disease among men who exercised.
Brisk walking before prostate cancer diagnosis is associated with more regularly-shaped blood vessels in the tumor.
Middle-aged men who are at a high fitness level have a reduced risk of developing and dying from lung cancer and colorectal cancer.
Certain forms of exercise can help combat fatigue and other side effects from cancer treatment, leading to improved outcomes for patients.
Physical activity improves physical functions and quality of life after cancer treatment
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy